UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 2, 2014
Immune Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
001-51290 |
52-1841431 | ||
|
(State or Other Juris- |
(Commission |
(IRS Employer | ||
|
diction of Incorporation) |
File Number) |
Identification No.) | ||
|
|
|
|
|
|
|
708 Third Avenue, Suite 210, New York, New York |
10591 | |||
|
(Address of Principal Executive Offices) |
(Zip Code) | |||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (914) 606-3500 | ||||
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
On April 2, 2014, Robert W. Cook, who was originally the Chief Financial Officer of EpiCept Corporation, resigned from his position as Chief Financial Officer of Immune Pharmaceuticals Inc. (the “Company”). Mr. Cook will remain in his position through the filing of the Company’s Annual Report on Form 10-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IMMUNE PHARMACEUTICALS INC. | ||||
|
Date: April 8, 2014 |
By: |
/s/ Daniel G. Teper | ||
|
Name: Daniel G. Teper | ||||
|
Title: Chief Executive Officer | ||||